摘要
目的:观察口服小剂量螺内酯对高血压患者血清结缔组织生长因子(CTGF)的影响,探讨螺内酯对高血压的治疗效果。方法:将我院2009年1月-2010年8月住院的60例高血压患者采用随机数字表法分为治疗组(30例)和对照组(30例)。治疗组给予口服螺内酯治疗,从10mg、tid开始,视病情程度增减用量;对照组给予口服氢氯噻嗪12.5mg,bid。2组疗程均为8周。测量患者治疗前后的血压、血糖、血总胆固醇及空腹血糖(FBG)。结果:治疗4周时治疗组总有效率为37%,8周时总有效率达74%,有效率明显高于治疗4周时,差异有统计学意义(P<0.05);SG、血总胆固醇治疗8周后治疗组与对照组比较无明显变化,舒张压与收缩压明显下降(P<0.05),血清CTGF明显下降(P<0.05)。对照组在治疗6周后,有5例出现SG、血低密度脂蛋白和甘油三酯升高等症状,遂停止服药。结论:小剂量螺内酯在不干扰体内脂质、糖等代谢的情况下能有效改善高血压患者血压,同时能明显降低体内血清的CTGF。
OBJECTIVE： To observe the effect of small-dose spironolactone on the serum CTGF in high blood pressure patients, and to investigate the therapeutic efficacy of spironolactone in the treatment of high blood pressure. METHODS： From Jan. 2009-Aug. 2010 60 high blood pressure patients were randomly divided into treatment group （30 cases） and control group （30 cases） using double blind method. Treatment group was given oral does of spironolactone 10 mg tid. and the dose of drugs increased or decreased according to disease condition. Control group was given oral dose of dihydrochlorothiazide 12.5 mg bid. Treatment course lasted for 8 weeks in both groups. The blood pressure, blood glucose, TC, SG and SI were determined before and after treatment. RESULTS： The total effective rate of treatment group was 37% at 4th week and 74% at 8th week. There was significant difference between 4th week and 8th week （P0.05）. There was significant difference in SG and TC between 2 groups, and systolic pressure and diastolic pressure decreases significantly （P0.05）. The level of serum CTGF decreased significantly （P0.05）. After 6 weeks treatment, the increased of SG, LDL and TG were found in 5 cases, then they stopped taking medicine. CONCLUSION： Small-dose spironolactone can improve the blood pressure of high blood pressure patients while decrease serum CTGF significantly under the circumstance of no interference to the lipid and sugar metabolism.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第20期1889-1891,共3页
China Pharmacy
关键词
高血压
螺内酯
结缔组织生长因子
治疗效果
High blood pressure
Spironolactone
Connective tissue growth factor
Therapeutic efficacy
